What are the implications of the 2007 USPTO policy change for pending applications with multiple nucleotide sequences?
The 2007 USPTO policy change, which rescinded the 1996 waiver allowing multiple nucleotide sequences in a single application, has specific implications for pending applications. MPEP 803.04 states: “All pending applications are subject to the 2007 OG notice. Note, however, that supplemental restriction requirements will not be advanced in applications that have already received an action…
Read MoreHow does the USPTO handle restriction requirements in otherwise allowable applications?
When an application is otherwise allowable but contains a traverse of a restriction requirement, the USPTO follows a specific procedure as outlined in MPEP 710.02(c): “Where an application is otherwise allowable but contains a traverse of a restriction requirement, the applicant may be given a specified time (e.g., a 2-month time limit) to cancel claims…
Read MoreNo Additional FAQs
All relevant information from MPEP 803.01 – Review by Examiner with at Least Partial Signatory Authority has been covered in previously generated FAQs. No additional meaningful questions can be formulated without redundancy or speculation beyond the provided content. To learn more: MPEP Patent Examination Restriction Requirements
Read More